Loading
A phase 2 trial of Patient-derived organoids in Non-muscle-invasive bladder cancer, run by Hospital Centre Biel/Bienne, not yet recruiting.
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids is a phase 2 interventional study registered as NCT06227065 by Hospital Centre Biel/Bienne, with 28 participants planned, started 2026-12-01 and due to reach its primary completion in 2030-11-30. Interventions recorded: Epirubicin, Mitomycin, Gemcitabine, Docetaxel. Conditions recorded: Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low Grade.
Linked to the technology Patient-derived organoids because the registry's title names it ("patient derived organoids") and Non-muscle-invasive bladder cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Docetaxel, Gemcitabine and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Gemcitabine and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Epirubicin, Docetaxel and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/